Evidence basis for antimalarial policy change in Sierra Leone: Five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine

Tropical Medicine and International Health

Volumn 10, Issue 2, 2005, Pages 146-153

  Checchi, Francesco ^a   Roddy, Paul ^b,c   Kamara, Sarian ^d   Williams, Arthur ^d   Morineau, Guy ^a   Wurie, Abdul Rahman ^e   Hora, Bona ^e   De Lamotte, Nadine ^b   Baerwaldt, Tim ^c   Heinzelmann, Annette ^c   Danks, Alison ^f   Pinoges, Loretxu ^a   Oloo, Aggrey ^g   Durand, Rémy ^h   Ranford Cartwright, Lisa ⁱ   De Smet, Martin ^b  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d MINISTRY OF HEALTH AND SANITATION   (Sierra Leone)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f World Health Organization ^*  (Sierra Leone)

^g WHO Regional Office for Africa   (Zimbabwe)

^h BICHAT HOSPITAL   (France)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Amodiaquine; Artesunate; Chloroquine; Efficacy; Malaria; Plasmodium falciparum; Policy; Sierra Leone; Sulphadoxine pyrimethamine

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; PIPERAQUINE;

CHILD HEALTH; DISEASE TREATMENT; HEALTH POLICY; MALARIA;

AFRICA; ARTICLE; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; FEVER; FOLLOW UP; GENE AMPLIFICATION; GENOTYPE; HEALTH CARE POLICY; HEMOGLOBIN DETERMINATION; HUMAN; IN VIVO STUDY; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PARASITE PREVALENCE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREGNANCY; PRESCHOOL CHILD; REINFECTION; SIERRA LEONE; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

AMODIAQUINE; ANIMALS; ANTIMALARIALS; CHILD, PRESCHOOL; CHLOROQUINE; DEVELOPING COUNTRIES; DRUG COMBINATIONS; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH POLICY; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SIERRA LEONE; SULFADOXINE; TREATMENT FAILURE; TREATMENT OUTCOME;

AFRICA; EASTERN HEMISPHERE; SIERRA LEONE; SUB-SAHARAN AFRICA; WEST AFRICA; WORLD;

ARTESUNATE; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 13944284218     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2004.01367.x     Document Type: Article

References (26)

1. Adjuik M, Agnamey P, Babiker A et al. (2002) Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359, 1365-1372.
2. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N & International Artemisinin Study Group (2004) Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363, 9-17.
3. Bachy C (2002) In vivo Study of the Efficacy of Chloroquine and Sulfadoxine-Pyrimethamine for Treatment of Uncomplicated Plasmodium falciparum Malaria. Southern Province of Sierra Leone, Epicentre/MSF report, Mattru, Bonthe District.
4. Bakshi R, Hermeling-Fritz I, Gathmann I & Alteri E (2000) An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 418-420.
5. Barnish G, Maude GH, Bockarie MJ, Erunkulu OA, Dumbuya MS & Greenwood BM (1993a) Malaria in a rural area of Sierra Leone. II. Parasitological and related results from pre- and post-rains clinical surveys. Annals of Tropical Medicine and Parasitology 87, 137-148.
6. Barnish G, Maude GH, Bockarie MJ, Eggelte TA & Greenwood BM (1993b) The epidemiology of malaria in southern Sierra Leone. Parassitologia 35 (Suppl.), 1-4.
7. Bjorkman A (2002) Malaria associated anaemia, drug resistance and antimalarial combination therapy. International Journal of Parasitology 32, 1637-1643.
8. Bousema JT, Gouagna LC, Meutstege AM et al. (2003) Treatment failure of pyrimethamine-sulfadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Tropical Medicine and International Health 8, 427-430.
9. Checchi F, Durand R, Balkan S et al. (2002a) High Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine in Harper, Liberia: results in vivo and analysis of point mutations. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 664-669.
10. Checchi F, Balkan S, Vonhm BT et al. (2002b) Efficacy of amodiaquine for uncomplicated Plasmodium falciparum malaria in Harper, Liberia. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 670-673.
11. Ministry of Health and Sanitation and Partners (2004) National Strategic Plan for Roll Back Malaria Implementation in Sierra Leone: 2004-2008. MoHS, Freetown.
12. Nosten F & Brasseur P (2002) Combination therapy for malaria: the way forward? Drugs 62, 1315-1329.
13. Olliaro P & Taylor WRJ (2003) Antimalarial compounds: from bench to bedside. Journal of Experimental Biology 206, 3753-3759.
14. Olumese PE, Amodu OK, Bjorkman A, Adeyemo AA, Gbadegesin RA & Walker O (2002) Chloroquine resistance of Plasmodium falciparum is associated with severity of disease in Nigerian children. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 418-420.
15. Ranford-Cartwright LC, Taylor J, Umasunthar T et al. (1997) Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 719-724.
16. Rwagacondo CE, Karema C, Mugisha V et al. (2004) Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Tropical Medicine and International Health 9, 1091-1098.
17. Snounou G, Zhu X, Siripoon N et al. (1999) Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene 93, 369-374.
18. Stepniewska K, Taylor WR, Mayxay M et al. (2004) In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrobial Agents and Chemotherapy 48, 4271-4280.
19. Talisuna AO, Langi P, Bakyaita N et al. (2002) Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 310-317.
20. Talisuna AO, Bloland P & D'Alessandro U (2004) History, dynamics, and public health importance of malaria parasite resistance. Clinical Microbiology Reviews 17, 235-254.
21. The East African Network for Monitoring Antimalarial Treatment (EANMAT) (2003) The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Tropical Medicine and International Health 8, 860-867.
22. Trape JF (2001) The public health impact of chloroquine resistance in Africa. American Journal of Tropical Medicine and Hygiene 64 (S1), 12-17.
23. van Vugt M, Wilairatana P, Gemperli B et al. (1999) Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 60, 936-942.
24. WHO (2003a) Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. WHO/HTM/RBM/2003.50, Geneva.
25. WHO (2003b) Position of WHO's Roll Back Malaria Department on Malaria Treatment Policy. Unpublished document. WHO, Geneva.
26. Zucker JR, Ruebush TK, Obonyo C, Otieno J & Campbell CC (2003) The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. American Journal of Tropical Medicine and Hygiene 68, 386-390.